FDA Issues Warning Letter to Abbott Over FreeStyle Libre CGM Accuracy Concerns
The U.S. Food and Drug Administration has issued a formal warning to Abbott Laboratories, citing significant quality control failures in the manufacturing and testing processes for its widely used FreeStyle Libre continuous glucose monitors.